Therefore, specific targeting of the Nrf2/HO-1 axis maybe a new therapeutic strategy for treatment of human diseases, such as Alzheimer's disease, diabetes, and hepatotoxicity [44, 46, 49, 50]. This evidence concerns the gene NFE2L2 and early-onset autosomal dominant Alzheimer disease.